COVID-19, caused by SARS-CoV-2, has resulted in over 550 million cases and more than 6.35 million deaths globally, with Mexico facing high incidence and mortality rates.
A critical aspect of severe COVID-19 involves hyperinflammatory responses, specifically elevated interleukin (IL)-6 levels and reduced T-CD8 and T-CD4 cells, particularly seen in severely ill patients.
Blood monocytes with a dual pro- and anti-inflammatory profile may serve as a predictive marker for COVID-19 protection in vaccinated individuals with mild symptoms, highlighting their potential role in immune response during the disease.